Cibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz - direct healthcare professional communication (DHPC)

abrocitinib / filgotinib / Baricitinib / upadacitinib / Tofacitinib

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi)

Key facts

• Medicine name:
  • Cibinqo
  • Jyseleca
  • Olumiant
  • Rinvoq
  • Xeljanz
• Active substance:
  • abrocitinib
  • filgotinib
  • Baricitinib
  • upadacitinib
  • Tofacitinib
• Therapeutic area (MeSH):
  • Arthritis, Rheumatoid
  • Dermatitis, Atopic
• Procedure number:
  EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003; EMEA/H-A20/1517/C/004085/0032; EMEA/H-A20/1517/C/004760/0017; EMEA/H-A20/1517/C/005113/0014
• Regulatory outcome:
  Variation
• DHPC type:
  Referral - Article 20 procedure
• Human ATC codes:
  • D11AH08
  • L04AA45
  • L04AA37
  • L04AA44
  • L04AA29
• Dissemination date:
  21/02/2023